Article thumbnail

CLINICALLY ISOLATED SYNDROME IN CHILDREN AND ADOLESCENTS — RISK FACTORS FOR MULTIPLE SCLEROSIS AND PROSPECTS OF USING INTRAMUSCULAR INTERFERON β-1A

By O.V. Bykova, A.N. Platonova, N.N. Shatilova, A.V. Anikin and L.M. Kuzenkova

Abstract

<p><em>The first demyelinating episode in the structure of multiple sclerosis is called clinically isolated syndrome, that is the clinical debut of the disease requiring an extensive differential diagnostic search and identification of long-term therapeutic tactics. It is well-known that experience of prescribing interferon β to adult patients at this earliest stage in the disease results in a substantially improved long-term disability prognosis. At the same time, promising techniques for an early launch of the biologic response modifier therapy have not yet found sufficient application in children and adolescents with multiple sclerosis.</em><br /><em><strong>Key words: multiple sclerosis, clinically isolated syndrome, children, adolescents, interferon</strong> <strong>β. </strong></em></p><p><em> <em>(Pediatric Pharmacology. – 2010; 7(3):91-94)</em></em></p

Topics: Therapeutics. Pharmacology, RM1-950
Publisher: Paediatrician Publishers, LLC
Year: 2010
OAI identifier: oai:doaj.org/article:c6c9b504340a4782afa8c0ecb2a739fb
Journal:
Download PDF:
Sorry, we are unable to provide the full text but you may find it at the following location(s):
  • https://doaj.org/toc/2500-3089 (external link)
  • https://doaj.org/toc/1727-5776 (external link)
  • http://pf.spr-journal.ru/jour/... (external link)
  • https://doaj.org/article/c6c9b... (external link)

  • To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.

    Suggested articles